Mirae Asset ramps up investment in biotech sector Mirae Asset Capital investing in more than 10 foreign biotech and healthcare firms
Translated by Kim So-in 공개 2021-09-06 07:49:49
이 기사는 2021년 09월 06일 07:38 thebell 에 표출된 기사입니다.
Mirae Asset Group is ramping up its investments in the biotech sector, with Mirae Asset Capital increasing its investment in foreign biotech and healthcare startups.Mirae Asset Capital has invested in more than 10 foreign biotech and healthcare companies in recent years, according to data compiled by the bell. Investments have been mostly funded through Mirae Asset-Celltrion New Growth Fund I, which closed at 150 billion won ($130 million) in 2017.
The fund, which was created jointly by Mirae Asset Group and Celltrion, is managed by Mirae Asset Capital. The duration of the fund is seven years since the inception. It mainly invests in companies that engage in new growth engines like biotech and healthcare, such as biomaterials firms, new drug developers, and medical device companies. The fund mostly focuses on late-stage investments instead of early-stage investments.
The fund participated in U.S.-based Vividion Therapeutics’ Series B funding round in 2019. The investment is expected to generate a hefty profit as Bayer recently agreed to acquire the firm for $1.5 billion.
The fund invested in bispecific antibody startup EpimAb Biotherapeutics in the fourth quarter of 2020. It also participated in Senti Biosciences and Valo Health’s Series B funding rounds.
The fund is making more active investments this year, investing in Omega Therapeutics, Iksuda Therapeutics, and HiFiBiO Therapeutics.
Mirae Asset Venture Investment also invested in five foreign biotech firms during the first six months of this year, including Israel-based KAHR Medical and Singapore-based Hummingbird Bioscience.
The move is part of Mirae Asset Group Chairman Park Hyeon-joo’s plans to invest 10 trillion won over the next 10 years in startups engaged in new growth engines such as biopharmaceutical and healthcare sectors. (Reporting by In-hyo Kang)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 에스트래픽, 적자 '일시적 현상'... 2분기 수익개선 기대
- [Company Watch]'자회사 회생신청' 투비소프트, 성과 없는 신사업
- '크라우드 펀딩' 와디즈, '테슬라 요건' 상장 추진
- [우리투자증권의 부활]그룹 황태자로 키울까…우리지주 '추가출자' 불가피
- [금융지주 CEO 책임경영 진단]진옥동 회장, 글로벌·자본시장 '톱 레벨' 기반 구축 경과는
- [라인야후 탈네이버 논란]주인 바뀐 라인넥스트, 블록체인 사업 추진 '오히려 좋아'
- [보험사 지급여력 돋보기]DB손보, 줄어든 '보험위험'에 버퍼 확보
- AI 외치는 삼성, 자신감·위기감 '공존'
- 시큐센, 1분기 매출 41억·영업손실 13억
- 콤텍시스템, 1분기 적자폭 감소 "AI 공격 투자"